Adverse Event Management
Better Treatment Needed for Androgen Receptor Adverse Events
February 23, 2021
Article
While the majority of patients on androgen receptor therapy experienced adverse events, more than a third did not have them resolved.
Patient Perceptions, Other Factors Linked to Fear of Recurrence
February 19, 2021
Article
Fear of cancer recurrence is a common plight for people after they have completed cancer treatment, and recent research analyzed which patient characteristics were associated with higher rates of fear of recurrence.
High TMB, Adverse Events May Predict Immunotherapy Response in mUC
February 17, 2021
Article
Patients with metastatic urothelial carcinoma with higher tumor mutational burden and who experienced immune-related adverse events tended to have higher response rates to immune checkpoint inhibitor.
Sapanisertib: Poor Activity, More AEs in mRCC
February 13, 2021
Article
Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status.
COVID-19 Amplifies Stress, Loneliness in Cancer Survivors
February 12, 2021
Article
The COVID-19 pandemic increased rates of stress in the general public, adding to that of survivors who may already be feeling anxious.
Discuss Mental Health in Testicular Cancer Survivorship Plans
February 06, 2021
Article
Testicular cancer survivors had a higher rate of mental health service utilization than their healthy counterparts.
Nonmedical Opioid Use: Identify the Risks
February 02, 2021
Podcast
A recent study found that 19% of patients with cancer engaged in nonmedical opioid use.
Mental Health Screening Is Needed in Blood Cancer Space
December 26, 2020
Article
Data from a recent analysis demonstrated that more than one in five people experienced depression or anxiety, either before or not long after receiving a blood cancer diagnosis, highlighting the need for further mental health screening in these individuals.
Managing GI AEs in Metastatic Breast Cancer
December 15, 2020
Article
Gastrointestinal (GI) adverse events (AEs) that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide, according to research presented at the 2020 San Antonio Breast Cancer Symposium.
CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning
November 29, 2020
Article
Following the approvals of tisagenlecleucel (tisa-cel; Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta), several research efforts have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas, according to Olalekan O. Oluwole, MBBS, MD, who added that although this modality has moved the needle forward, this approach is not without toxicity.